NGM Biopharmaceuticals(NGM) - 2019 Q3 - Quarterly Report

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jur ...